Nearly half of Americans are chronically deficient in the mineral that powers over 300 enzymatic reactions — and most people taking magnesium supplements are using a form their body can barely absorb. Here is what the clinical evidence actually says.
Magnesium deficiency is not a niche problem. It is one of the most prevalent nutritional shortfalls in the developed world — and three structural forces have converged to make it almost inevitable.
Modern industrial agriculture depends on NPK (nitrogen, phosphorus, potassium) fertilizers that do not replace magnesium. A 2004 study published in the Journal of the American College of Nutrition found reliable declines of 5–40% in the magnesium content of vegetables compared to 1950 USDA data. The magnesium in spinach, almonds, and dark chocolate that your grandmother ate was genuinely higher than what you are eating today. (Davis DR et al., JACN 2004)
Refining whole grains into white flour removes approximately 80% of the magnesium content. Modern diets heavy in ultra-processed foods — which now account for over 57% of caloric intake in American adults per a 2016 BMJ Open analysis — deliver far less magnesium than equivalent whole-food diets. The average American gets roughly 260 mg per day from diet alone, against an RDA of 420 mg for men and 320 mg for women. (Martini LA et al., Nutr Rev 2012; Moubarac JC, BMJ Open 2017)
Chronic psychological stress elevates cortisol and catecholamines, which drive magnesium out of cells into urine. Stress-induced magnesium loss then impairs the stress-response system — creating a self-amplifying loop. A 1994 study in Magnesium Research demonstrated that psychological stress in humans measurably increased urinary magnesium excretion within 24 hours. This partly explains why modern, high-stress populations have lower measured magnesium status independent of diet. (Galland L, Magnes Res 1994)
Add to this the magnesium-depleting effects of common medications — proton pump inhibitors, loop diuretics, certain antibiotics, and alcohol — and it becomes clear why deficiency is structural, not exceptional.
Magnesium is the second most abundant intracellular cation in the human body. Unlike calcium, which functions largely as a signaling ion, magnesium is a structural and catalytic workhorse embedded in biochemical machinery at every level.
Every molecule of adenosine triphosphate (ATP) — the universal energy currency of the cell — must be chelated with magnesium to be biologically active. The functional form of ATP in the body is Mg-ATP. Without adequate intracellular magnesium, cellular energy production is literally impaired at the molecular level. This underlies why magnesium deficiency presents clinically as fatigue, weakness, and poor exercise recovery. (Romani AM, Arch Biochem Biophys 2011)
Magnesium acts as a physiological calcium antagonist at the NMDA receptor — the major excitatory glutamate receptor in the central nervous system. Adequate magnesium maintains the Mg²⁺ block of NMDA channels, preventing excessive neuronal excitation. When brain magnesium is low, NMDA receptors become hyperactive, producing effects including heightened anxiety, sleep disruption, and in severe cases, seizure susceptibility. (Slutsky I et al., Neuron 2010)
Magnesium regulates vascular smooth muscle tone, cardiac conduction, and platelet aggregation. Epidemiological data consistently show inverse relationships between magnesium intake and hypertension, cardiac arrhythmia, and cardiovascular mortality. A 2013 meta-analysis in the American Journal of Clinical Nutrition found each 100 mg/day increase in magnesium intake was associated with an 8% reduced risk of total cardiovascular disease. (Qu X et al., AJCN 2013)
Magnesium is required for the autophosphorylation of the insulin receptor and for downstream glucose transporter (GLUT4) activity. Low magnesium is independently associated with insulin resistance and type 2 diabetes. A landmark 2004 study in Diabetes Care found hypomagnesemia predicted development of type 2 diabetes over a 15-year follow-up, independent of other metabolic risk factors. (Kao WH et al., Diabetes Care 2004)
Magnesium stabilizes the structure of ribosomes and is required for peptide bond formation during protein synthesis. It is also an essential cofactor for DNA polymerases and repair enzymes. Adequate magnesium status is therefore relevant not just to energy and mood, but to long-term cellular integrity and genomic stability.
Not all magnesium is equal. The anion bound to the magnesium cation determines how well it is absorbed, where it goes in the body, and what it is most useful for clinically.
| Form | Bioavailability | Best For | Elemental Dose | Key Study |
|---|---|---|---|---|
| Glycinate | ~80% | Sleep, anxiety, muscle | 200–400 mg | Schuette SA et al. (1994) — superior absorption vs. oxide in controlled comparison |
| L-Threonate | ~75% + BBB | Cognition, memory | 144 mg (from 2g MgT) | Slutsky I et al., Neuron (2010) — 15% increase in brain Mg, improved synaptic density |
| Malate | ~70% | Energy, fatigue, fibromyalgia | 300–600 mg | Russell IJ et al., J Rheumatol (1995) — significant reduction in fibromyalgia pain scores |
| Citrate | ~60–70% | General, constipation | 200–400 mg | Walker AF et al., Magnes Res (2003) — citrate superior to oxide for serum/urinary Mg |
| Taurate | ~65% | Cardiovascular, blood pressure | 125–250 mg | Shechter M et al., Am J Cardiol (2000) — improved endothelial function in CAD patients |
| Oxide | ~4% | Laxative only | Not recommended | Firoz M & Graber M, Magnes Res (2001) — lowest fractional absorption of all tested forms |
While every well-absorbed form provides the baseline benefits of correcting deficiency, glycinate and threonate stand out for distinct pharmacokinetic and mechanistic reasons.
Glycinate is magnesium chelated with two molecules of glycine — the simplest amino acid, and the primary inhibitory neurotransmitter of the brainstem and spinal cord. The chelation serves two purposes. First, it dramatically improves intestinal absorption by allowing the amino acid transporter system (rather than just the slower paracellular magnesium pathway) to facilitate uptake. Second, the glycine itself is bioactive.
Glycine activates glycine receptors in the central nervous system, exerting inhibitory effects on arousal circuits. A 2012 study in Sleep and Biological Rhythms found oral glycine (3g before bed) improved sleep quality, reduced daytime sleepiness, and improved sleep onset latency in subjects with sleep complaints — effects that may compound with magnesium's NMDA antagonism. (Bannai M et al., Sleep Biol Rhythms 2012)
The practical result is a form that corrects deficiency efficiently and provides dual anxiolytic and sleep-promoting activity through two independent mechanisms — magnesium's NMDA block and glycine's receptor agonism. There is no other magnesium form with this dual mechanism.
Threonate was developed specifically to address a limitation of all other magnesium forms: they raise serum magnesium but do not reliably elevate brain magnesium. The blood-brain barrier has active transport mechanisms for magnesium, and the modest concentration gradient achieved by oral supplementation with most forms is insufficient to significantly increase cerebrospinal fluid (CSF) magnesium levels.
Magnesium L-threonate was designed at MIT to overcome this. The 2010 Slutsky et al. paper in Neuron was the foundational proof-of-concept: MgT increased brain magnesium by 15% compared to control, enhanced synaptic density in the prefrontal cortex and hippocampus, and improved both short-term and long-term memory in rodent models. Critically, these effects were not replicated by magnesium sulfate at the same elemental dose — confirming it is the threonate carrier, not just magnesium, driving central penetration.
A 2016 randomized, double-blind human trial published in the Journal of Alzheimer's Disease found MgT supplementation significantly improved cognitive measures in older adults with mild cognitive impairment over 12 weeks, with participants' brains showing functional improvements equivalent to being 9 years younger on the assessed measures. (Liu G et al., J Alzheimers Dis 2016)
The trade-off is cost and elemental dose — 2,000 mg of MgT delivers only about 144 mg of elemental magnesium. For total-body magnesium repletion, threonate must be paired with another form such as glycinate.
Look for chelated magnesium bisglycinate with no oxide fillers. 200–400 mg elemental per serving. Ideal for sleep, anxiety, and daily magnesium repletion.
View Magnesium Glycinate on AmazonThe only form clinically demonstrated to raise cerebrospinal magnesium. Typically 1,500–2,000 mg MgT per day. Best stacked with glycinate for full-spectrum coverage.
View Magnesium L-Threonate on AmazonThe RDA for magnesium is 420 mg/day for men and 310–320 mg/day for non-pregnant women (350–360 mg during pregnancy). These numbers represent dietary intake required to prevent deficiency in most healthy people under ideal conditions. They are floors, not targets.
Therapeutic supplementation protocols — used in research settings for sleep, cognitive function, anxiety, and blood pressure — typically deliver 200–400 mg of elemental magnesium from supplemental sources, on top of dietary intake. The upper tolerable intake level (UL) set by the Institute of Medicine is 350 mg/day of supplemental magnesium for adults; above this, the risk of osmotic diarrhea increases (with poorly absorbed forms like citrate). Well-absorbed chelated forms like glycinate are generally better tolerated near or above the UL.
Labels list the compound weight, not elemental magnesium. Always check the Supplement Facts panel for elemental magnesium per serving. A "500 mg magnesium citrate" capsule contains roughly 100–130 mg of elemental magnesium. A "400 mg magnesium glycinate" capsule may contain 50–80 mg elemental. This discrepancy is how people underestimate their actual intake.
Serum magnesium is the standard clinical test ordered by most physicians — and it is a poor proxy for tissue magnesium status. The body regulates serum magnesium tightly within a narrow range (0.75–0.95 mmol/L) through renal reabsorption, bone resorption, and cellular efflux. Serum levels can remain "normal" while intracellular magnesium is substantially depleted.
A serum magnesium below the reference range (frank hypomagnesemia) is clinically significant, but a normal serum result does not rule out functional deficiency. As many as 40% of people with documented magnesium deficiency at tissue level have normal serum magnesium. (Elin RJ, Magnesium 1987)
RBC (red blood cell) magnesium measures intracellular magnesium concentration within red blood cells, which better reflects tissue stores. Reference range is approximately 4.2–6.8 mg/dL. This test is available through specialty labs and provides a more clinically actionable picture of magnesium status. If you suspect deficiency, request RBC magnesium — not serum magnesium.
Based on the evidence, here is how to structure a comprehensive magnesium protocol across three goals: deficiency correction, cognitive support, and cardiovascular optimization.